5 hours Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue EstimatesZacks
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X